Corcept Therapeutics Incorporated (CORT) Posts Positive Phase 2 BELLA Data

What happened

Corcept reported positive Part A results from its Phase 2 BELLA trial of Lifyorli combined with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The trial showed median PFS of 7.2 months and an ORR of 59%, while median OS was not reached at primary analysis.

Confirmed

Global impact / market context

Positive trial results can improve the chance of regulatory approval and wider insurance coverage for Lifyorli, which could increase Corcept's future revenue from ovarian cancer. Strong response rates may also encourage doctors to choose this combination, helping the company compete in a difficult cancer market.

Analyst inference

Corcept is expanding its oncology business after the ROSELLA study. The article says a randomized study or label expansion to include bevacizumab, plus mature overall survival data, would be needed to create a larger stock catalyst. That suggests investors may treat these results as encouraging but not final proof.

Analyst inference

What to watch

1. The article states that median overall survival was not reached at primary analysis, meaning longer follow-up is needed to see whether a survival benefit appears. Confirmed
2. A randomized study is suggested as a next step; such a trial would compare the regimen against standard treatment and could support broader regulatory labeling. Proposed
3. Regulatory moves to expand Lifyorli's label to include bevacizumab would matter; approval could widen eligible patients and support revenue, while failure would limit the drug's market. Analyst inference

Evidence

• Original source link unavailable